You are here

Clinical Trials: Cord Blood


Body: Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Body: Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
Sponsor:   Masonic Cancer Center, University of Minnesota
Body: Condition:   Severe Combined Immunodeficiency
Interventions:   Biological: unrelated BM with T cell depletion;   Biological: unrelated cord blood;   Biological: haplo BM with T cell depletion;   Device: unrelated PBSC with T cell depletion
Sponsor:   Neena Kapoor, M.D.
Body: Conditions:   Sickle Cell Disease;   Sickle Cell Anemia;   SCD
Interventions:   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplant (HSCT)
Sponsor:   Case Comprehensive Cancer Center
Recruiting - verified July 2017
Body: Condition:   Alzheimer's Disease
Interventions:   Biological: human umbilical cord blood derived mesenchymal stem cells;   Other: Normal saline 2mL
Sponsor:   Medipost Co Ltd.
Recruiting - verified April 2017
Body: Condition:   Sensorineural Hearing Loss
Intervention:   Genetic: Autologous Stem Cells
Sponsors:   James Baumgartner, MD;   CBR Systems, Inc.
Body: Condition:   Crohn's Disease
Intervention:   Biological: Stem cells
Sponsor:   Kang Stem Biotech Co., Ltd.
Recruiting - verified September 2016
Body: Condition:   Cerebral Palsy
Interventions:   Biological: Autologous Stem Cells;   Other: Saline Infusion (Placebo)
Sponsors:   The University of Texas Health Science Center, Houston;   Cord Blood Registry, Inc.;   Let's Cure CP Foundation;   Mission Connect, a program of TIRR Foundation
Active, not recruiting - verified June 2017
Body: Condition:   Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor
Intervention:   Other: Cord Blood Transplantation
Sponsor:   Assistance Publique - Hôpitaux de Paris
Body: Conditions:   Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions:   Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
Sponsor:   University of Pittsburgh
Recruiting - verified March 2017
Body: Conditions:   EBV;   CMV;   Adenovirus
Interventions:   Drug: CTL for CMV seropositive donors;   Drug: CTL for CMV naïve donors
Sponsor:   Catherine Bollard
Recruiting - verified May 2017
Body: Conditions:   Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions:   Other: Treg-enriched infusion;   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Miltenyi Biotec GmbH;   Prometheus Laboratories;   National Cancer Institute (NCI)
Recruiting - verified July 2017
Body: Conditions:   Single Umbilical Cord Blood Transplantation;   Non-myeloablative Conditioning;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia
Intervention:   Drug: HSC835
Sponsor:   Novartis Pharmaceuticals
Completed - verified July 2017
Body: Condition:   Blood And Marrow Transplantation
Intervention:   Drug: Eltrombopag
Sponsors:   M.D. Anderson Cancer Center;   Novartis Pharmaceuticals
Recruiting - verified April 2017
Body: Conditions:   CMV;   EBV;   Adenovirus Infections
Intervention:   Drug: Cytotoxic T lymphocytes (CTLs).
Sponsors:   Children's Research Institute;   M.D. Anderson Cancer Center